Astrazeneca plc
NASDAQ: AZN
$76.99
-$0.95 (-1.2%)
Closing Price on July 2, 2024
AZN Articles
Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance is that Pfizer may now simply be having an identity crisis.
Published:
These are the top Wall Street analyst upgrades, downgrades and initiations seen after the three-day Memorial Day weekend. They include AMC, Cisco, NextEra, NRG and Staples.
Published:
Source: ThinkstockBig news from two of the market’s biggest names is making waves across Wall Street today as stocks advance through a quiet start to the week. The Dow Jones Industrial...
Published:
Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced that it had sold the business to Germany-based Bayer for $14.2 billion.
Published:
Last Updated:
Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower in the premarket.
Published:
Last Updated:
British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion (about £50 a share) in cash and stock.
Published:
Last Updated:
These are the top analyst upgrades, downgrades and initiations for Tuesday, April 22, 2014. They include AMD, ARM Holdings, Barrick Gold, Netflix, Teva Pharmaceutical and Valero Energy.
Published:
Source: ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion range? AstraZeneca PLC (NYSE:...
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, March 3, 2014. They include Apple, MarkWest Energy Partners, NII Holdings, RF Micro...
Published:
Source: ThinkstockHorizon Pharma Inc. (NASDAQ: HZNP) is having a stellar day after breaking news that it entered into a pact with AstraZeneca PLC (NYSE: AZN) for the U.S. rights to VIMOVO. The move...
Published:
Source: ThinkstockMerck & Co. (NYSE: MRK) announced it would rid itself of 8,500 workers, many of whom work in the big pharmaceutical company’s R&D operations. Since the return on research...
Published:
Source: ThinkstockInvestors make big money in biotechnology stocks when they focus on areas that cut across a wide swath of the population. From obesity to food allergies to prostate cancer, the top...
Published:
Source: ThinkstockWith yields on 10-year Treasury bonds up nearly 1.5% since early May and briefly touching 3.0% last week, the impact of higher rates on stocks continues to be top of mind for...
Published:
Source: Jon OggInvestors are on the hunt for solid research ideas now that stocks have pulled back a bit. 24/7 Wall St. reviews many analyst research calls from Wall Street and from boutique firms to...
Published:
Source: ThinkstockAlthough Amgen Inc.’s (NASDAQ: AMGN) $10 billion offer for Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) was unsolicited and not exactly a stalking horse bid, that’s what many...
Published:
Last Updated: